NAV

NasoVAX

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
NasoVAX
Accession Number
DB15859
Description

NasoVAX contains replication-deficient adenovirus vectors in suspension. It is a vaccine administered through a nasal spray that expresses influenza hemagglutinin in nasal epithelial cells1. Created by Altimmune, Inc., NasoVAX is currently being developed for seasonal and pandemic use as it can activate humoral and cellular immune responses. The compound has already shown to be tolerated with no adverse effects or fever in healthy individuals with a nearly 6-fold cellular immune response in comparison to an injectable vaccine1. As of June 2020, NasoVAX is being evaluated in a Phase 2 clinical trial for safety and effectivness in preventing worsening symptoms in hospitalized COVID-19 patients (NCT04442230).

Type
Biotech
Groups
Investigational
Synonyms
Not Available
External IDs
  • NasoVAX

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication
Not Available
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Open Forum Infectious Diseases on NasoVAX [Link]
  2. AltImmune NasoVAX [Link]
  3. News on NasoVAX [Link]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedPreventionFlu caused by Influenza1
2RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19) / Infections, Coronavirus1
Not AvailableCompletedNot AvailableFlu caused by Influenza1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on September 17, 2020 21:23 / Updated on September 18, 2020 08:47